Cargando…

Targeting CAM-DR and Mitochondrial Transfer for the Treatment of Multiple Myeloma

The prognosis of patients with multiple myeloma (MM) has improved dramatically with the introduction of new therapeutic drugs, but the disease eventually becomes drug-resistant, following an intractable and incurable course. A myeloma niche (MM niche) develops in the bone marrow microenvironment and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suzuki, Rikio, Ogiya, Daisuke, Ogawa, Yoshiaki, Kawada, Hiroshi, Ando, Kiyoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689110/ https://www.ncbi.nlm.nih.gov/pubmed/36354732 http://dx.doi.org/10.3390/curroncol29110672

Ejemplares similares

Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myeloma
por: Suzuki, Rikio, et al.
Publicado: (2020)

Clinicopathological evaluation of methotrexate-associated lymphoproliferative disorders with special focus on Epstein-Barr virus-positive mucocutaneous lesions
por: Shiraiwa, Sawako, et al.
Publicado: (2020)

Overcoming Tyrosine Kinase Inhibitor Resistance in Transformed Cell Harboring SEPT9-ABL1 Chimeric Fusion Protein
por: Kawai, Hidetsugu, et al.
Publicado: (2019)

Refractory acute promyelocytic leukemia successfully treated with combination therapy of arsenic trioxide and tamibarotene: A case report
por: Kojima, Minoru, et al.
Publicado: (2016)

A Case of Composite Lymphoma with Extranodal NK/T-cell Lymphoma, Nasal-type and Diffuse Large B-cell Lymphoma
por: Kawai, Hidetsugu, et al.
Publicado: (2019)

Identification of a novel SEPT9-ABL1 fusion gene in a patient with T-cell prolymphocytic leukemia
por: Suzuki, Rikio, et al.
Publicado: (2014)

Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma
por: Minakata, Daisuke, et al.
Publicado: (2023)

The Successful Prevention of Thromboembolism Using Rivaroxaban in a Patient with Antithrombin Deficiency during the Perioperative Period
por: Kawai, Hidetsugu, et al.
Publicado: (2017)

Jagged1-induced Notch activation contributes to the acquisition of bortezomib resistance in myeloma cells
por: Muguruma, Yukari, et al.
Publicado: (2017)

Elucidating the expression and function of Numbl during cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma (MM)
por: Huang, Yuejiao, et al.
Publicado: (2019)

Suppression of multiple myeloma by mitochondrial targeting
por: Aisen, Yana, et al.
Publicado: (2021)

Dose-adjusted EPOCH-R in patients with newly diagnosed diffuse large B-cell lymphoma harboring MYC rearrangement
por: Kojima, Minoru, et al.
Publicado: (2020)

Primary CNS post-transplant lymphoproliferative disorder following haploidentical HSCT using post-transplant high-dose cyclophosphamide
por: Toyosaki, Masako, et al.
Publicado: (2018)

Dose‐escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma
por: Iida, Shinsuke, et al.
Publicado: (2016)

Mitochondrial Kv1.3 Channels as Target for Treatment of Multiple Myeloma
por: Kadow, Stephanie, et al.
Publicado: (2022)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

Four hepatosplenic T-cell lymphoma cases of Japanese patients
por: Kawai, Hidetsugu, et al.
Publicado: (2015)

Cadherins, Selectins, and Integrins in CAM-DR in Leukemia
por: Kim, Hye Na, et al.
Publicado: (2020)

Stromal Cells Serve Drug Resistance for Multiple Myeloma via Mitochondrial Transfer: A Study on Primary Myeloma and Stromal Cells
por: Matula, Zsolt, et al.
Publicado: (2021)

Myc-Related Mitochondrial Activity as a Novel Target for Multiple Myeloma
por: Ortiz-Ruiz, Alejandra, et al.
Publicado: (2021)

CAM-DR: Mechanisms, Roles and Clinical Application in Tumors
por: Huang, Yuejiao, et al.
Publicado: (2021)

Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells
por: Suzuki, Rikio, et al.
Publicado: (2015)

Impact of mitochondrial DNA mutations in multiple myeloma
por: Hoang, Phuc H., et al.
Publicado: (2020)

The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma
por: Faict, Sylvia, et al.
Publicado: (2019)

Targeted Therapies for Multiple Myeloma
por: Leow, Christopher Chang-Yew, et al.
Publicado: (2021)

Targeted therapy of multiple myeloma
por: Zhou, Shan, et al.
Publicado: (2021)

Model of translational cancer research in multiple myeloma
por: Yasui, Hiroshi, et al.
Publicado: (2012)

Multiple Myeloma and Kidney Disease
por: Katagiri, Daisuke, et al.
Publicado: (2013)

Outcomes of poor peripheral blood stem cell mobilizers with multiple myeloma at the first mobilization: A multicenter retrospective study in Japan
por: Miyamoto‐Nagai, Yurie, et al.
Publicado: (2022)

The Effect of Roxadustat on Transfusion-Dependent Myelodysplastic Syndrome Complicated by Chronic Kidney Disease
por: Hara, Ryujiro, et al.
Publicado: (2021)

Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics
por: Ogiya, Daisuke, et al.
Publicado: (2023)

Small Molecule Multi-Targeted Kinase Inhibitor RGB-286638 Triggers P53-Dependent and -Independent Anti-Multiple Myeloma Activity through Inhibition of Transcriptional CDKs
por: Cirstea, Diana, et al.
Publicado: (2013)

Targeting the UPS as therapy in multiple myeloma
por: Chauhan, Dharminder, et al.
Publicado: (2008)

Targeting the Pim kinases in multiple myeloma
por: Keane, N A, et al.
Publicado: (2015)

Molecularly Targeted Therapies in Multiple Myeloma
por: de la Puente, Pilar, et al.
Publicado: (2014)

Bone-targeted agents in multiple myeloma
por: Nishida, Hiroko
Publicado: (2018)

Immunotherapeutic and Targeted Approaches in Multiple Myeloma
por: Nadeem, Omar, et al.
Publicado: (2020)

Targeted Therapy With Immunoconjugates for Multiple Myeloma
por: Bruins, Wassilis S. C., et al.
Publicado: (2020)

BCMA-targeted immunotherapy for multiple myeloma
por: Yu, Bo, et al.
Publicado: (2020)

Targeting phosphoglycerate dehydrogenase in multiple myeloma
por: Elsaadi, Samah, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_engal6vbvashtmunjvs5bgavu2